Background
Materials and methods
Patient characteristics and data collection
Identification of differentially expressed genes and enrichment analysis
Assessment of tumor-infiltrating immune cells
Identification of a predictive gene-signature of postoperative seizure occurrence
Weighted correlation network analysis
Identification of hub genes
Construction of a prediction model for postoperative seizure occurrence
Statistical analysis
Results
Baseline patient characteristics
Variable | Training cohort | Validation cohort |
---|---|---|
Total number | 166 | 42 |
Gender | ||
Male | 101 (60.8%) | 19 (45.2%) |
Female | 65 (39.2%) | 23 (54.8%) |
Age at diagnosis (years) | 45 (14–72)a | 44 (19–68) a |
< 45 | 88 (53.0%) | 18 (42.9%) |
≥ 45 | 78 (47.0%) | 24 (57.1%) |
Tumor side | ||
Left | 71 (42.8%) | 21 (50.0%) |
Right | 87 (52.4%) | 17 (40.5%) |
Bilateral | 7 (4.2%) | 4 (9.5%) |
Frontal lobe involvement | ||
Involved | 105 (63.3%) | 27 (64.3%) |
None | 61 (36.7%) | 15 (35.7%) |
Temporal lobe involvement | ||
Involved | 73 (44.0%) | 13 (31.0%) |
None | 93(56.0%) | 29 (69.0%) |
Neuro-function deficit | ||
Yes | 46 (27.7%) | 16 (38.1%) |
No | 120 (72.3%) | 26 (61.9%) |
Preoperative GRE | ||
GRE | 62 (37.3%) | 15 (35.7%) |
Non-GRE | 104 (62.7%) | 27 (64.3%) |
Postoperative GRE | ||
GRE | 30 (18.1%) | 7 (16.7%) |
Non-GRE | 136 (81.9%) | 35 (83.3%) |
EOR | ||
GTR | 81 (48.8%) | 26 (61.9%) |
Non-GTR | 85 (51.2%) | 16 (38.1%) |
WHO grade | ||
3 | 99 (59.6%) | 27(64.3%) |
4 | 67 (40.4%) | 15 (35.7%) |
Tumor pathology | ||
AA | 68 (41.0%) | 15 (35.7%) |
AO | 31 (18.7%) | 12 (28.6%) |
GBM | 67 (40.3%) | 15 (35.7%) |
IDH1/2 mutation | ||
Mutation | 83 (50.0%) | 26(61.9%) |
Wild type | 83(50.0%) | 16 (38.1%) |
Chromosome 1p/19q codeletion† | ||
Codeletion | 42 (25.3%) | 13 (31.0%) |
Non-codeletion | 111 (66.9%) | 28 (69.0%) |
MGMT promoter‡ | ||
methylated | 81 (48.8%) | 22 (52.4%) |
unmethylated | 61 (36.7%) | 17 (40.5%) |
Concurrent Radio-chemotherapy | ||
Yes | 124 (74.7%) | 29 (69.0%) |
No | 39 (23.5%) | 13 (31.0%) |
Identification and enrichment analysis of DEGs
Construction of a predictive gene-signature for postoperative seizure occurrence
Gene Name | Gene Title | Gene Function | β |
---|---|---|---|
LUZP2 | Leucine zipper protein 2 | Extracellular matrix development | 0.000647 |
GPNMB | Glycoprotein nmb | Cell–cell signaling | 0.002348 |
MMD2 | Monocyte to macrophage differentiation-associated 2 | Protein kinase activity | 0.003071 |
GALNT13 | Polypeptide N-acetylgalactosaminyltransferase 13 | Metal ion binding | 0.005717 |
IKBKGP1 | Inhibitor of nuclear factor kappa B kinase subunit gamma pseudogene 1 | None | 0.014818 |
SLC1A4 | Solute carrier family 1 member 4 | Synaptic transmission, glutamatergic | 0.019691 |
RP1 | RP1 axonemal microtubule associated | Intracellular signal transduction | 0.019902 |
Identification of hub genes associated with the obtained gene-signature and GRE
Gene Name | Gene Title | Gene Function | Gene Expression | p-value | |
---|---|---|---|---|---|
High | Low | ||||
CD38 | CD38 molecule | Signal transduction | 9.37 | 2.98 | 8.20858E-09 |
KCNJ10 | Potassium inwardly rectifying channel subfamily J member 10 | ATP-activated inward rectifier Potassium channel activity | 41.13 | 21.04 | 4.92146E-10 |
KCNN3 | Potassium calcium-activated channel subfamily N member 3 | Small conductance calcium-activated potassium channel activity | 10.04 | 3.12 | 4.31468E-09 |
NRG3 | Neuregulin 3 | Modulation of chemical synaptic transmission | 5.55 | 1.64 | 3.05726E-10 |
SELL | Selectin L | Calcium ion binding | 26.01 | 5.64 | 0.000682892 |
SFRP2 | Secreted frizzled related protein 2 | Receptor ligand activity | 46.26 | 4.58 | 1.09581E-08 |
Construction of an integrated prediction model for the occurrence of postoperative seizure
Variable | p-value | OR | 95% CI |
---|---|---|---|
Age | 0.046 | 0.944 | 0.892–0.990 |
Temporal lobe involvement | 0.011 | 5.414 | 1.480–19.804 |
Preoperative GRE | 0.047 | 4.120 | 1.017–16.688 |
Risk-score | < 0.001 | 17.766 | 4.756–66.350 |